Eloxx Cagey With Phase 2 Mono Cystic Fibrosis Data
Insights - Eloxx (ELOX) shared monotherapy data from their Phase 2 in cystic fibrosis this morning. The data that was reported was not bad, but it left investors wanting … Continue Reading
PremiumSearch Results for gene therapy
More AFM13+NK MD Anderson Data Likely in Mid-December
Insights - Affimed (AFMD) announced a few updates this morning with ASH nearing. Overall, little substance was shared, which was disappointing as we were expecting AFM13+NK data … Continue Reading
Premium
Names To Watch With XBI Hit
Insights - Biotech (XBI) is back under $125 after a small September rally. On biotech weakness, we’re looking to buy companies on our watchlist or add to … Continue Reading
Premium
This Name Is Overlooked While Rest of IL-2 Space Is In A Frenzy
Research - Medicenna (MDNA) is developing a next-gen IL-2 candidate against solid tumors. The company expects to report Phase 1 biomarker data by the end of 2021, … Continue Reading
PremiumEloxx Setting Expectations for Phase 2 CF Data
Insights - Eloxx (ELOX) provided a Q2 business update earlier this week, and everything was on schedule. Based on enrollment at the end of June, the company remainson track to report … Continue Reading
PremiumConference: Medicenna (MDNA) CEO On Their Drug’s Best-in-Class Potential in IL-2 Space
Digital Conferences - Transcript of Digital Conference Participants Fahar Merchant – President & Chief Executive Officer, Medicenna Mann Muhsin – Chief Medical Officer, Medicenna Elizabeth Williams – Chief … Continue Reading
Read now
FDA Places Magenta’s ADC Conditioning Program On Hold
Insights - Magenta announced that the FDA has placed a clinical hold on their IND filed in June 2021 for conditioning agent MGTA-117. As a result, MGTA will need … Continue Reading
Premium